Sage Therapeutics SAGE 深 沪
等待开盘 02-05 09:30:00 美东时间
8.68
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.68
- 总市值 5.44亿
- 52周最高 9.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.62
- 委 比 0.00%
- 总股本 6262.23万
- 历史最高 195.97
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.62
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Supernus Pharmaceuticals Clears Antitrust Hurdle For Sage Therapeutics Acquisition In $8.50/Share Cash Offer Plus Up To $3.50/Share In Contingent Value Rights Merger
Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supern
2025-07-28 20:27
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
2025-07-28 12:25
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals (NASDAQ:KALV), Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their produ...
2025-07-25 21:23
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
6 analysts have expressed a variety of opinions on Sage Therapeutics (NASDAQ:SA...
2025-07-08 22:00
Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2
Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform and lowers the price target from $12 to $9.2.
2025-07-08 20:26
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
2025-06-21 08:35
Analysts’ Top Healthcare Picks: Surgery Partners (SGRY), SAGE Therapeutics (SAGE)
Analysts fell to the sidelines weighing in on Surgery Partners (SGRY – Research...
2025-06-18 17:10
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
2025-06-18 09:46
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of June 17, 2025, three stocks in the health care sector could be flashing a...
2025-06-17 20:31
